Mycobacterial Diseases
Open Access

Advancing TB Treatment with Artificial Intelligence

Fuhang Lia^{* *}Correspondence: Fuhang Lia, Department of Bacteriology and Immunology, Capital Medical University, Beijing, China, Email:

Author info »

Description

Despite advancements in TB treatment, the disease claims over 1.5 million lives annually, and the rise of Multidrug-Resistant Tuberculosis (MDR-TB) poses a significant threat to public health. Traditional methods of diagnosis, treatment, and management are often time-consuming and costly, which has prompted the exploration of innovative technologies to improve outcomes [1]. Artificial Intelligence (AI) has emerged as a powerful tool in revolutionizing TB treatment, diagnosis, and drug development, offering new hope in the fight against this deadly disease.

AI in TB diagnosis and detection

One of the most promising applications of AI in tuberculosis care is in improving diagnostic accuracy and speed. Traditional diagnostic methods for TB, such as sputum microscopy, chest Xrays, and GeneXpert testing, have limitations in terms of accessibility, cost, and sensitivity. AI can enhance these methods, making TB diagnosis faster and more accessible, particularly in resource-limited settings [2]. AI has shown significant potential in improving the accuracy of chest X-rays, a common tool for TB diagnosis. AI algorithms can analyze chest X-ray images to detect TB-related abnormalities with a high degree of accuracy, often outperforming human radiologists. These algorithms can help clinicians identify TB in its early stages, even in patients with atypical presentations [3]. AI-driven tools like Computer-Aided Detection for Tuberculosis (CAD4TB) are already being used in various countries to screen large populations quickly and costeffectively, particularly in areas with limited access to skilled radiologists. AI-based software can also analyze data from molecular tests such as GeneXpert, which detects TB bacteria and drug resistance. These systems can speed up the interpretation of results and provide clinicians with more accurate and detailed information about the patient’s infection status. By reducing human error and speeding up the diagnostic process, AI can help ensure that patients receive timely and appropriate treatment.

AI and drug-resistant TB

The rise of drug-resistant TB, particularly MDR-TB and Extensively Drug-Resistant TB (XDR-TB), poses a significant challenge to treatment. AI can play a crucial role in addressing this issue by helping identify drug resistance more efficiently and developing more effective treatment regimens. AI algorithms can analyze genetic data from TB bacteria to predict which strains are resistant to specific antibiotics [4]. This allows healthcare providers to customize treatment regimens to individual patients, ensuring they receive the most effective drugs. Machine learning models trained on vast datasets of bacterial genomes can identify patterns that suggest drug resistance, often before it becomes clinically apparent [5]. This capability can be critical in curbing the spread of drug-resistant TB strains. AI can also assist in optimizing TB treatment regimens. Traditionally, TB treatment involves a combination of antibiotics taken over several months. However, treatment regimens for drug-resistant TB are more complex, often requiring a longer duration and the use of second-line drugs with more severe side effects [6]. AI models can analyze clinical data from thousands of patients to identify the most effective drug combinations with the least side effects, potentially reducing treatment duration and improving patient outcomes.

AI in drug discovery and development

Developing new TB drugs is a lengthy and costly process. AI has the potential to accelerate this process by predicting how new compounds will interact with Mycobacterium tuberculosis, the bacteria that cause TB. AI-powered drug discovery platforms can screen millions of chemical compounds in a fraction of the time it would take using traditional methods [7]. By analysing vast datasets of molecular structures and biological activity, AI can identify promising compounds that could serve as new TB drugs. These platforms can also predict the efficacy and safety of these compounds, allowing researchers to focus on the most potential candidates. AI can also be used to identify existing drugs that may be repurposed for TB treatment. By analysing data from past clinical trials, patient outcomes, and drug interactions, AI models can identify drugs that could be effective against TB, even if they were originally developed for other diseases [8]. This approach has the potential to significantly shorten the timeline for developing new TB treatments.

AI in monitoring and adherence to treatment

Ensuring that TB patients complete their treatment regimens is critical to preventing the development of drug-resistant strains and ensuring successful outcomes. AI can help in this area by improving patient monitoring and treatment adherence [9]. AIpowered mobile apps can remind patients to take their medication, track side effects, and provide real-time feedback to healthcare providers. Some apps use machine learning algorithms to predict when a patient is likely to miss a dose, allowing for timely intervention. These systems can also analyze data from wearable devices to monitor patients' health during treatment, detecting early signs of complications or relapse. AI can also be used to develop more effective strategies for ensuring treatment adherence [10]. For example, AI systems can analyze patterns in patient behaviour and predict when a patient is at risk of discontinuing treatment. By identifying these risks early, healthcare providers can intervene with personalized support, helping patients stay on track and reducing the likelihood of relapse.

Conclusion

AI is transforming the way tuberculosis is diagnosed, treated, and managed. From improving diagnostic accuracy to optimizing treatment regimens and speeding up drug discovery, AI offers new tools to fight TB more effectively. As AI technologies continue to evolve, their integration into global TB control strategies could significantly reduce the burden of this disease, particularly in areas hardest hit by TB and drug-resistant strains. By harnessing the power of AI, we can move closer to the goal of eliminating tuberculosis worldwide.

References

1. Liang S, Ma J, Wang G, Shao J, Li J, Deng H, et al. The application of artificial intelligence in the diagnosis and drug resistance prediction of pulmonary tuberculosis. Front Med. 2022;9:935080.

   [Crossref] [Google Scholar] [PubMed]

2. Dande P, Samant P. Acquaintance to artificial neural networks and use of artificial intelligence as a diagnostic tool for tuberculosis: A review. Tuberculosis. 2018;108:1-9.

   [Crossref] [Google Scholar] [PubMed]

3. Cao XF, Li Y, Xin HN, Zhang HR, Pai M, Gao L. Application of artificial intelligence in digital chest radiography reading for pulmonary tuberculosis screening. Chron Dis Transl Med. 2021;735-40.

   [Crossref] [Google Scholar] [PubMed]

4. Zhang F, Zhang F, Li L, Pang Y. Clinical utilization of artificial intelligence in predicting therapeutic efficacy in pulmonary tuberculosis. J Infect Public Health. 2024;17:632-641.

   [Crossref] [Google Scholar] [PubMed]

5. Shi Y, Zhang C, Pan S, Chen Y, Miao X, He G, et al. The diagnosis of tuberculous meningitis: Advancements in new technologies and machine learning algorithms. Front Microbiol. 2023;14:1290746.

   [Crossref] [Google Scholar] [PubMed]

6. Dohál M, Porvazník I, Solovič I, Mokrý J. Advancing tuberculosis management: The role of predictive, preventive, and personalized medicine. Frontiers Microbiol. 2023;14:1225438.

   [Crossref] [Google Scholar] [PubMed]

7. Pandey SK, Singh KU, Dingankar RS, Jadhav K, Gupta K, Yadav RK. Prediction of tuberculosis disease progression with AI analysis of clinical data. IEEE. 2023;1:1-6.

   [Crossref] [Google Scholar]

8. Chen X, Chen F, Liang C, He G, Chen H, Wu Y, et al. MRI advances in the imaging diagnosis of tuberculous meningitis: Opportunities and innovations. Front  Microbiol. 2023;14:1308149.

   [Crossref] [Google Scholar] [PubMed]

9. Talat A, Khan AU. Artificial intelligence as a smart approach to develop antimicrobial drug molecules: A paradigm to combat drug-resistant infections. Drug Discov Today. 2023;28(4):103491.

   [Crossref] [Google Scholar] [PubMed]

10. Xiong Y, Ba X, Hou A, Zhang K, Chen L, Li T. Automatic detection of mycobacterium tuberculosis using artificial intelligence. J Thorac Dis. 2018;10(3):1936.

    [Crossref] [Google Scholar] [PubMed]